Bruker Corp
NASDAQ:BRKR
Bruker Corp
NASDAQ:BRKR
Price:
74.33 USD
2.5%
Market Closed
Updated:
May 8, 2024
P/S
Price to Sales
Price to Sales
3.6
Current
4
Median
3.9
Industry
Lower
than median
Lower
than industry value
Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.
P/S
=3.6
Market Cap
/
10.8B
Revenue
3B
All Countries
| Market Cap | P/S | ||||
|---|---|---|---|---|---|
| US |
|
Bruker Corp
NASDAQ:BRKR
|
10.8B USD | 3.6 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
221.5B USD | 5.2 | |
| US |
|
Danaher Corp
NYSE:DHR
|
184.2B USD | 4.2 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.6B USD | 2.8 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
56.4T KRW | 15.3 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
41.4B USD | 6.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
38.1B CHF | 5.7 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
26.9B USD | 9.2 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.9B USD | 7.1 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
26B USD | 3.2 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
19.3B EUR | 7.1 |
P/S Forward Multiples
Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/S
3.2
2-Years Forward
P/S
3
3-Years Forward
P/S
2.9
You don't have any saved screeners yet
